Table 3 Factors associated with successful TB treatment outcomes among HIV/TB co-infected patients in East and North Eastern Uganda.

Distance to the health facility

≤ 5 km

46(50.5)

160(69.6)

1

1

> 5 km

45(49.5)

70(30.4)

0.44(0.27–0.74)

0.002

0.88(0.65–1.18)

0.405

Baseline weight

<49.6

53(60.2)

112(49.3)

1

1

≥ 49.6

35(39.8)

115(50.7)

1.55(0.94–2.56)

0.084

1.04(0.79–1.36)

0.799

TB classification

Extra pulmonary TB

7(7.7)

7(3.0)

1

1

Pulmonary bacteriologically confirmed (PBC) TB

62(68.1)

160(68.7)

2.58(0.87, 7.66)

0.088

0.80(0.36–1.77)

0.581

Pulmonary clinically diagnosed (PCD) TB

22(24.2)

66(28.3)

3.00(0.94, 9.51)

0.062

1.00(0.45–2.23)

0.996

Treatment history

New case

85(93.4)

205(88.4)

1

Retreatment case

5(5.5)

26(11.2)

2.16(0.80, 5.80)

0.128

1.08(0.698–1.67)

0.727

Treatment history unknown

1(1.1)

1(0.4)

0.41(0.03, 6.71)

0.535

1.06(0.145–7.76)

0.954

WHO HIV clinical stage at baseline

Stage 1

19(57.6)

37(27.2)

0.72(0.39–1.32)

0.286

0.99(0.67–1.48)

0.976

Stage 2

1(3.0)

6(4.4)

2.38(0.28, 20.04)

0.425

1.11(0.48–2.56)

0.808

Stage 3

7(21.2)

85(62.5)

6.89(3.05, 15.58)

< 0.001

1.02(0.73–1.43)

0.896

Stage 4

6(18.2)

8(5.9)

0.50(0.17, 1.49)

0.216

0.73(0.33–1.58)

0.420

ART enrollment status

No

15(16.5)

24(10.3)

Yes

76(83.5)

208(89.7)

1.71(0.85, 3.43)

0.131

1.22(0.78–1.93)

0.400

Follow up at 5 months for sputum monitoring

Yes

5 (5.5)

157 (67.4)

No

86 (94.5)

76 (32.6)

0.48(0.37–0.64)

< 0.001

0.48(0.34–0.66)

< 0.001